Search

Aboriginal and Torres Strait Islander resources

A number of organisations have created COVID-19 resources specifically developed for Aboriginal and Torres Strait Islander people.

A letter to you

A letter to the WA public from Jonathan Carapetis and Fiona Stanley.

Schools and COVID

The Kids Research Institute Australia position on schools and COVID-19 in Western Australia

National Community Advisory Group

Engaging the community in COVID-19 rapid research

Reduce impact on families

The research that is reducing the impact on families done by The Kids Research Institute Australia.

Ask an expert

Ask our experts a question about the COVID-19 pandemic.

ORIGINS community wellbeing during the COVID-19 pandemic

Desiree Dr Jackie Lisa Susan Silva Davis Gibson Prescott MBBS, FRACP, MPH, PhD BSc (Hons), PGradDipHlthProm, PhD BA (Hons), MPsych, PhD MBBS BMedSci

Perth researchers lead world-first clinical trial in Chile to stop COVID-19 outbreaks

Perth researchers are leading an international clinical trial focused on preventing the spread of COVID-19 by testing the effectiveness of the drug interferon in reducing the infectiousness of people who contract the virus.

Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics

Children with chronic medical diseases are at an unacceptable risk of hospitalisation and death from influenza and SARS-CoV-2 infections. Over the past two decades, behavioural scientists have learnt how to design non-coercive 'nudge' interventions to encourage positive health behaviours. Our study aims to evaluate the impact of multicomponent nudge interventions on the uptake of COVID-19 and influenza vaccines in medically at-risk children.

The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.